Company news
Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A (SSE:688192) news
Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 6, 2025: Announcement on Attending Collective Performance Briefing…
Press releases — page 2
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 5, 2025
Announcement on Resolutions of the 15th Meeting of the 2nd Board of Directors
August 22, 2025
The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
August 6, 2025
Announcement on Inclusion of Global Registered Clinical Study on Zegfrovy in the Oral Presentation at the 2025 World Conference on Lung Cancer (WCLC) and the Selection of Multiple Studies In the Field of Non-Small Cell Lung Cancer
July 23, 2025
Announcement on Result of Shareholding Reduction by Senior Management Member
July 8, 2025
Announcement on Cancellation of Partial Special Accounts for Raised Funds
July 4, 2025
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
July 1, 2025
Announcement on Release of Pledge of Partial Shares of Shareholder
June 30, 2025
Announcement on Share Reduction Plan for Senior Management Members
June 25, 2025
Announcement on the Listing and Circulation of Some Restricted Shares in Initial Public Offering
June 23, 2025
Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
June 19, 2025
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
June 12, 2025
Notice on Convening the 2024 Annual General Meeting
May 28, 2025
Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025
May 26, 2025
Voluntary Disclosure Announcement on the Release of the Latest Research Results of DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Conference
May 23, 2025
Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences
May 15, 2025
Announcement on Result of Share Reduction by Director and Senior Management Member
May 8, 2025
2024 Annual Report
April 29, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
April 25, 2025
Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025
April 24, 2025
Announcement on Results of Issuing Shares to Specific Objects and Changes in Capital Stock
April 21, 2025
Announcement on Voluntary Disclosure of Golidocitinib's Inclusion in the Level-I Recommendation of the CSCO Guidelines for the Diagnosis and Treatment of Lymphoma (2025 Edition)
April 18, 2025
Announcement on Correction to the Signing of Agreement on Supervision over Deposit in Special Account for Raised Funds
April 16, 2025
Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting
April 1, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
March 25, 2025
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
March 20, 2025
Announcement on Documents like Prospectus (Registration Draft) for Issuance of Shares to Specific Objects
March 9, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 24, 2025
Announcement on Obtaining Registration Approval of Application for Issuance of Shares to Specific Objects by China Securities Regulatory Commission
February 7, 2025